

Leucemia de Células Cabeludas (Tricoleucemia)

Tratamento padrão:

Cladribina: 0,1 mg/kg/dia IV infusão contínua por 7 dias (ciclo único).

Opções do uso de cladribina:

- a. 0,14 mg/Kg/dia IV, infundir durante 2h por 5 dias
- b. 0,14 mg/Kg IV, infundir durante 2h uma vez por semana
- c. 0,14 mg/Kg SC, uma vez por semana

Avaliar associação de rituximabe 375 mg/m², IV na HCL variante Ref. (01)

1. Saven A, *et al.* Blood 1998;92:1918-26.

Lauria F, Bocchia M, Marotta G, Raspadori D, Zinzani PL, Rondelli D. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. *Haematologica*. 1999;84(1):22–25.

Golomb HM. Hairy cell leukemia: treatment successes in the past 25 years. *J Clin Oncol*. 2008;26(16):2607–2609.

Robak T, Jamroziak K, Gora-Tybor J, *et al.* Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. *Blood*. 2007;109(9):3672–3675.

Juliusson G, Liliemark J. Purine analogues: rationale for development, mechanisms of action, and pharmacokinetics in hairy cell leukemia. *Hematol Oncol Clin North Am*. 2006;20(5):1087–1097.

Zinzani PL, Tani M, Marchi E, *et al.* Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. *Haematologica*. 2004;89(3):309–313.

Zenhausern R, Schmitz SF, Solenthaler M, *et al.* Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). *Leuk Lymphoma*. 2009:1–11.